Last updated on June 2019

Study of Efficacy of PEAR-004 in Schizophrenia.


Brief description of study

The purpose of the study is to determine in patients currently being administered antipsychotic pharmacotherapy whether PEAR-004 can further reduce symptoms of schizophrenia as measured by the Positive and Negative Syndrome Scale (PANSS).

The overall rationale for the study is to assess the first prescription digital therapeutic (PDT) in schizophrenia using a form of proven psychosocial intervention, cognitive behavioral therapy (CBT), to supplement standard of care with antipsychotic medications.

 

Clinical Study Identifier: TX220936

Find a site near you

Start Over

Collaborative Neuro Science Network

12772 Valley View Suite 3 Garden Grove, United States
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.